Welcome to our dedicated page for Humana SEC filings (Ticker: HUM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Humana Inc. (NYSE: HUM) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports on Form 8-K, annual reports on Form 10-K and quarterly reports on Form 10-Q as they are filed with the U.S. Securities and Exchange Commission. As a major participant in Medicare Advantage, Medicaid managed care and related health insurance lines, Humana uses these filings to report financial results, guidance, leadership changes and other material events.
Recent Form 8-K filings for Humana include Regulation FD disclosures reaffirming earnings guidance and providing reconciliations between GAAP earnings per common share and Adjusted earnings per common share (Adjusted EPS), which management uses to analyze core operating performance and inform planning and incentive compensation. Other 8-Ks describe results of operations for specific quarters, preliminary Medicare Advantage Star Ratings information, and leadership transitions in the insurance segment, such as the planned retirement of an Insurance Segment President and the appointment of new leaders for Medicare Advantage and the broader insurance business.
Filings also reflect Humana’s role as a health insurer and managed care organization. AM Best’s rating actions, while separate from SEC filings, complement the picture provided in regulatory reports by describing the financial strength and business profile of Humana’s health and dental insurance subsidiaries, collectively known as Humana Health Group, and by noting the contribution of the CenterWell segment as a non-insurance source of revenue and earnings.
On Stock Titan, investors and researchers can use AI-powered summaries to quickly interpret lengthy documents such as 10-K and 10-Q reports, focusing on topics that matter for a company like Humana: Medicare Advantage and Medicaid performance, Star Ratings dynamics, non-GAAP metrics like Adjusted EPS, capital structure, and risk disclosures. The filings page also surfaces insider and executive-related disclosures reported on Form 8-K, helping users track leadership changes and compensation-related arrangements referenced in those reports. Real-time updates from EDGAR combined with AI explanations make it easier to follow how Humana communicates its financial condition, strategic initiatives and regulatory developments over time.
Humana Inc. President & CEO James A. Rechtin reported routine equity award activity on January 8, 2026. A total of 2,183 restricted stock units converted into the same number of Humana common shares at $0 per share under the company’s 2019 Amended & Restated Stock Incentive Plan.
Of these shares, 980 Humana common shares were withheld at a price of $279.1475 per share to satisfy tax obligations related to vesting, with no value received in return. Following these transactions, 28,305 Humana common shares were beneficially owned indirectly through two revocable trusts for the benefit of Rechtin and his spouse, where they serve as sole trustees.
Rechtin also holds stock options covering 29,230 Humana shares at an exercise price of
Humana Inc. director David T. Feinberg reported equity transactions in company stock and stock units. On 01/02/2026, he acquired 766 shares of Humana common stock at a reported price of $0, increasing his directly held beneficial ownership to 1,207 shares.
The filing also details changes in his deferred restricted stock units (RSUs). An existing block of 1,593 RSUs remains outstanding, each representing the right to receive one share of Humana common stock. On 12/31/2025, he elected to convert a director cash fee into 70 stock units and reinvest a dividend into 29 stock units, both deferred and valued at $258.8675 per unit, bringing their respective RSU balances to 708 and 46 units. All units are payable in Humana common stock on a 1-for-1 basis under the company’s equity plan and are reported as exempt under Rule 16b-3.
Humana Inc. director Wayne A. I. Frederick reported equity transactions in Humana common stock. The filing shows a disposition of 440 shares of Humana common stock in Table I.
In Table II, he acquired 766 restricted stock units on 01/02/2026 and 35 restricted stock units on 12/31/2025, each tied to Humana common stock. Following these transactions, he directly beneficially owned 3,174 restricted stock units from the first line and 73 from the second.
According to the footnotes, the larger grant represents an annual director’s fee payable in stock units under Humana’s 2019 Amended & Restated Plan, while the smaller amount reflects dividends reinvested into stock units. Both types of units are deferred until he resigns as a director, when they will be settled in Humana common stock on a one-for-one basis.
Humana Inc. director John W. Garratt reported equity awards and his updated holdings. On 12/31/2025, he acquired 16 restricted stock units tied to dividend payments, and on 01/02/2026 he acquired 766 restricted stock units as part of his annual director fee. These stock units are deferred until he resigns as a director, when they will be settled in Humana common stock on a 1-for-1 basis under the company’s 2019 Amended & Restated Plan.
Following these transactions, he directly beneficially owns 1,685 shares of Humana common stock. He also beneficially owns 1,929 restricted stock units described in note (1) and 18 restricted stock units described in note (2) as derivative securities, each corresponding to one share of Humana common stock upon settlement.
Humana Inc. director reports equity transactions and updated holdings. Director Marcy S. Klevorn reported activity in Humana common stock and related stock units. The filing shows a disposition of 436 shares of Humana common stock in the non-derivative section. In the derivative section, she acquired 766 restricted stock units as part of her annual director’s fee, which is payable in stock units deferred until her resignation, and 28 additional stock units from a director’s dividend payment reinvested at a price of $258.8675 per unit. Following these transactions, she beneficially owns 2,771 restricted stock units tied to Humana common stock under one award and 53 units under the dividend reinvestment award, each representing a contingent right to receive one share of Humana common stock on a 1-for-1 basis.
Humana Inc. director Frank A. D'Amelio reported new and existing equity holdings in the company. On 01/02/2026, he acquired 766 restricted stock units, which represent a contingent right to receive Humana common stock under the company’s 2019 Amended & Restated Plan. These units, along with other deferred stock units, are generally payable in Humana common stock on a 1-for-1 basis after his resignation as a director.
The filing shows a total of 26,826 restricted stock units held directly after the reported transaction, plus additional deferred stock units from converting director cash fees (2,467 units) and reinvested dividends (318 units). It also notes 20,634 Humana common shares held indirectly in a 2024 Grantor Retained Annuity Trust for which he serves as sole trustee.
Humana Inc. director Jorge S. Mesquita reported receiving 766 restricted stock units of Humana common stock on 01/02/2026. These units represent a contingent right to receive one share of Humana common stock for each unit and are noted as exempt under Rule 16b-3(d)(1)&(3) pursuant to the company's 2019 Amended & Restated Plan.
Following this grant, a total of 4,127 Humana shares, including the 766 restricted stock units, are reported as beneficially owned indirectly through a revocable trust where Mesquita is the sole trustee.
Humana Inc. director Kurt J. Hilzinger reported routine equity compensation activity. On 12/31/2025, he acquired restricted stock units tied to his director compensation and dividend reinvestment, including 611 units from reinvested dividends and 357 units from electing to convert cash fees into stock units at a price of $258.8675 per unit. On 01/02/2026, he received an additional 766 restricted stock units as part of his annual director fee, all payable in Humana common stock on a 1-for-1 basis after his board service ends.
Following these transactions, Hilzinger directly beneficially owns 19,448 Humana common shares and holds multiple blocks of deferred restricted stock units, including 24,800 units in one plan-based award. These awards are reported as exempt under Rule 16b-3 and reflect compensation elections rather than open-market buying or selling.
Humana Inc. director Karen W. Katz reported changes in her equity holdings. The filing shows a disposition of 590 shares of Humana common stock. She also reported derivative holdings in the form of restricted stock units (RSUs).
On 01/02/2026, Katz acquired 766 RSUs, which are part of her annual director’s fee payable in stock units and deferred until her resignation, when they will convert into Humana common stock on a one-for-one basis. On 12/31/2025, she acquired an additional 49 RSUs, related to dividend reinvestment on vested and deferred stock units at a price of $258.8675 per underlying share. Some director cash fees were also elected to be converted into deferred stock units, all payable in Humana common stock on a one-for-one basis upon her resignation.
Humana Inc. director Gordon Smith reported changes in his equity holdings. A Form 4 filing shows he disposed of 765 shares of Humana common stock and received additional equity-based awards tied to his director compensation.
The filing reports 766 restricted stock units from his annual director fee, which are deferred and will convert into Humana common stock on a 1-for-1 basis when he leaves the board. It also shows 122 stock units from electing to convert his cash director fees into stock units and 10 additional stock units from the reinvestment of dividends on previously vested and deferred units. All of these awards are structured as deferred stock units payable in Humana common stock, consistent with the company’s director compensation and deferral plan.
FAQ
What is the current stock price of Humana (HUM)?
What is the market cap of Humana (HUM)?
